Metformin as adjunctive therapy in combination with multidrug treatment for multibacillary leprosy: A protocol for a randomized double-blind, controlled Phase 2 trial in Indonesia (MetLep Trial)

Author:

Krismawati Hana,Muchtar Sri V.,Rahardjani Mutia,Oktaviani Margareta,. Syamsiah,Imbiri Nelly,Hasvitasari Dian,Fajrianti Dwi,Tarino Nico,Wulandari Fitri,Kestelyn EvelyneORCID,van Crevel ReinoutORCID,Walker Steve,Geskus RonaldORCID,Geluk Annemieke,Hamers Raph L.,Soebono HardyantoORCID,Grijsen Marlous L.ORCID

Abstract

Background: The clinical management of leprosy is complicated by leprosy reactions (LR) causing irreversible nerve damage and disabilities. LR often require long-term use of corticosteroids causing serious side effects. Adjunct host-directed therapy (HDT) is a potentially attractive strategy in leprosy to prevent LR and associated immunopathology, modulate immunological memory that protects against recurrence, and thereby reduce nerve damage, disability and corticosteroid-associated morbidities. Metformin, a well-tolerated, safe and cheap anti-hyperglycaemic drug, is repurposed as HDT in auto-immune and infectious diseases, like tuberculosis (TB). Metformin use in people with diabetes is associated with reduced risks of TB-infection, progression to active TB, treatment failure and TB-mortality. Given the similarities both mycobacteria share, we hypothesize that among persons with multibacillary (MB) leprosy, adjunctive metformin may prevent/mitigate LR. Methods: We will perform a double-blind controlled proof-of-concept trial in which people with newly diagnosed multibacillary leprosy will be randomized (1:1) to metformin hydrochloride 1000mg extended release once daily versus placebo for 24 weeks in addition to standard-of-care WHO MB multidrug therapy (MDT) during 48 weeks. We aim to enrol 166 participants aged between 18 and 65 years, across five clinical sites in two leprosy endemic areas in Indonesia. Primary endpoints are the proportion of participants experiencing a LR and the frequency of (serious) adverse events. Secondary endpoints are the severity and time to first LR, the number of LR, the cumulative corticosteroid usage, and quality of life. The total study follow-up is 48 weeks. Discussion: LR signify the most important cause of irreversible nerve damage leading to anatomical deformities and disabilities, imposing a social and financial burden on those affected. Our study aims to evaluate the efficacy, tolerability and safety of adjunct metformin added to MDT in persons with multibacillary leprosy, and explore its effects on clinical and immunological endpoints. ClinicalTrials.gov registration: NCT05243654 (17/02/2022)

Funder

Wellcome Trust

Leprosy Research Initiative and Turing Foundation

Publisher

F1000 Research Ltd

Subject

General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)

Reference71 articles.

1. Global leprosy (Hansen disease) update, 2019: time to step-up prevention initiatives.;Weekly epidemiological record.,2020

2. Profil Kesehatan Indonesia Tahun 2019.;B Hardhana,2020

3. Leprosy now: epidemiology, progress, challenges, and research gaps.;L Rodrigues;Lancet Infect Dis.,2011

4. Can baseline ML Flow test results predict leprosy reactions? An investigation in a cohort of patients enrolled in the uniform multidrug therapy clinical trial for leprosy patients in Brazil.;E Hungria;Infect Dis Poverty.,2016

5. Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India.;D Lockwood;Int J Lepr Other Mycobact Dis.,1993

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3